In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.
When discussing GLP-1 receptor agonists for patients with type 2 diabetes, it is important to know which adverse events may occur and which are myths.
For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.
Read which GLP-1 RA I favor for patients with type 2 diabetes who are overweight or obese.
How I use an oral GLP-1RA in the clinic.